6-(Dimethylamino)-4,4-diphenyl-3-heptanon-hydrochlorid

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Achtung

• Gefahrenhinweise

  H300：Lebensgefahr bei Verschlucken.

  H336：Kann Schläfrigkeit und Benommenheit verursachen.

Methadone hydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden

• R-Sätze Betriebsanweisung:

  R25:Giftig beim Verschlucken.
  R39/23/24/25:Giftig: ernste Gefahr irreversiblen Schadens durch Einatmen, Berührung mit der Haut und durch Verschlucken.
  R23/24/25:Giftig beim Einatmen, Verschlucken und Berührung mit der Haut.
  R11:Leichtentzündlich.

• S-Sätze Betriebsanweisung:

  S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
  S36/37:Bei der Arbeit geeignete Schutzhandschuhe und Schutzkleidung tragen.

• Beschreibung

  (±)-Methadone (hydrochloride) (Item No. ISO00145) is an analytical reference material categorized as an opioid. (±)-Methadone has analgesic activity. Formulations containing (±)-methadone have been used in the treatment of opioid addiction. (±)-Methadone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.

• Chemische Eigenschaften

  White Solid

• Originator

  Dolophine ,Lilly,US,1947

• Verwenden

  Controlled substance (opiate). Methadone hydrochloride is used in treatment of opioid dependence.

• Definition

  A synthetic narcotic.

• Manufacturing Process

  Diphenylacetonitrile is condensed with 2-chloro-1-dimethylaminopropane to give 4-(dimethylamino)-2,2-diphenyl valeronitrile. It is then reacted with ethyl magnesium bromide and then hydrolyzed using HCl to give methadone hydrochloride.

• Trademarks

  Dolophine Hydrochloride (Roxane); Dolophine Hydrochloride (Xanodyne); Methadose (Mallinckrodt); Westadone (Sandoz).

• Therapeutic Function

  Narcotic analgesic

• Hazard

  Toxic. Addictive narcotic. Use restricted.

• Clinical Use

  
  Treatment of opioid drug addiction
  Analgesic for moderate to severe pain

• Arzneimittelwechselwirkung

  Metabolised in the liver to the Potentially hazardous interactions with other drugs Analgesics: possible opioid withdrawal with buprenorphine and pentazocine. Antibacterials: metabolism increased by rifampicin; increased risk of ventricular arrhythmias with delamanid and telithromycin. Antidepressants: concentration possibly increased by fluoxetine, fluvoxamine, paroxetine and sertraline; possible CNS excitation or depression with MAOIs and moclobemide - avoid; possibly increased sedative effects with tricyclics; concentration possibly reduced by St John's wort. Antiepileptics: concentration reduced by carbamazepine, phenobarbital and phenytoin. Antifungals: concentration increased by fluconazole, ketoconazole, voriconazole and possibly itraconazole - may need to reduce methadone dose with voriconazole, avoid with ketoconazole. Antihistamines: increased sedative effects with sedating antihistamines.
  Antimalarials: increased risk of ventricular arrhythmias with piperaquine with artenimol - avoid.
  Antipsychotics: enhanced hypotensive and sedative effects; increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval - avoid with amisulpride.
  Antivirals: methadone possibly increases
  concentration of zidovudine; concentration reduced by efavirenz, fosamprenavir and ritonavir; concentration possibly reduced by abacavir, nevirapine and rilpivirine; concentration possibly affected by boceprevir; concentration of didanosine possibly reduced; increased risk of ventricular arrhythmias with saquinavir and telaprevir - avoid with saquinavir and use with caution with telaprevir.
  Atomoxetine: increased risk of ventricular arrhythmias.
  Cytotoxics: possible increased risk of ventricular arrhythmias with bosutinib, ceritinib, panobinostat and vandetanib.
  Dopaminergics: avoid with selegiline.
  Nalmefene: avoid concomitant use.
  Sodium oxybate: enhanced effect of sodium oxybate - avoid

• Stoffwechsel

  Metabolised in the liver to the major metabolite 2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine and the minor metabolite 2-ethyl-3,3-diphenyl-5- methylpyrrolidine, both of them inactive. Two other metabolites have also been identified. These metabolites are excreted in the faeces and urine with unchanged methadone

• läuterung methode

  The salt crystallises from EtOH, or EtOH/Et2O.

Methadone hydrochloride Upstream-Materialien And Downstream Produkte

1095-90-5, Methadone hydrochloride Verwandte Suche: